41 results on '"Combarel, David"'
Search Results
2. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care
3. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
4. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
5. Management of Pain Medication in Patients With a History of Bariatric Surgery: A Systematic Review
6. A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer.
7. Amniotic Aaquaporins (AQP) in Normal and Pathological Pregnancies: Interest in Polyhydramnios
8. Brief Report: Targeted Therapies and Pancreatic Toxicity in Patients with Lung Cancer, Retrospective Study and Recommendations
9. 36 Evaluation of transplacental transfer of cancer therapies in melanoma via the perfused human placental model
10. 119 Transplacental transfer of alectinib and osimertinib using an ex vivo human placental perfusion model
11. Association of serum angiogenic factors with bronchopulmonary dysplasia. The ANGIODYS cohort study
12. Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
13. Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
14. Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
15. Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
16. Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
17. Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
18. Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
19. Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
20. Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
21. Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
22. Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
23. Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
24. Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
25. Data from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
26. Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
27. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
28. Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
29. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions
30. Development and Validation of a Fast Ultra-High Performance Liquid Chromatography–Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus
31. Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails".
32. Abstract P4-11-24: Patient's point of view on how to promote adherence to adjuvant endocrine therapy (ET): A large french survey
33. Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer
34. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC
35. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma
36. Association of cabozantinib residual concentration (Ctrough) and blood clearance (Cl/F) with toxicity (tox) and progressive disease (PD) in metastatic renal cell carcinoma (mRCC) patients (pts): Results from a monocentric pharmacokinetics (PK) study.
37. Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
38. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
39. Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
40. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
41. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.